AXL and osteosarcoma: For example, cabozantinib, which can simultaneously inhibit VEGFRs, KIT, RET, PDGFRβ, MET, and AXL (21, 22), has the best effect in the treatment of osteosarcoma, with a median PFS of 6.2 months, compared to other TKIs listed in Table 1 and Figure 3 (20).